The Data Management and Statistics Core provide statistical consulting, data management and information transfer resources to enhance the quality of Alzheimer's disease research conducted by the ADRC investigators.
The specific aims are: 1. To provide database support to the Cores and Projects. To coordinate the entry, quality control, management and analysis of data generated by the enrollment, evaluation, and follow up of outpatient and control subjects recruited by the Centers Clinical Core. Similarly, to coordinate the entry, quality control, management and analysis of data generated by the Center's Neuropathology Core. 2. To prepare the ADRC database for routine submission to the National Alzheimer's Coordinating Center (NACC). 3. To provide statistical design and analysis consultation services to ADRC investigators. Design consultation power calculations and statistical analysis planning. Data analysis support ranges from providing simple descriptive statistics to the conduct of complex multivariate statistical analyses. 4. To develop new statistical methodology focused on application to Alzheimer's disease data. 5. To educate investigators, trainees and junior faculty in the principles and use of statistical analysis methodologies.

Public Health Relevance

AD affects millions of Americans with its risk growing exponentially with age. The AD Centers Program fosters research related to AD and non-AD dementias. The ADRC will enhance the performance of innovative research on AD and related topics, including research that may lead to potential disease modifying therapies or behavioral treatments. It will provide an environment and core resources to enhance research, foster professional and community training, and coordinate interdisciplinary research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005131-30
Application #
8449627
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
30
Fiscal Year
2013
Total Cost
$275,540
Indirect Cost
$57,494
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Ronquillo, Jay Geronimo; Baer, Merritt Rachel; Lester, William T (2016) Sex-specific patterns and differences in dementia and Alzheimer's disease using informatics approaches. J Women Aging 28:403-11
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-20
Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90
Besser, Lilah M; Alosco, Michael L; Ramirez Gomez, Liliana et al. (2016) Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition. J Neuropathol Exp Neurol 75:955-962
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2016) Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. Arch Gerontol Geriatr 65:231-8
de Wilde, Martijn C; Overk, Cassia R; Sijben, John W et al. (2016) Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement 12:633-44
John, Samantha E; Gurnani, Ashita S; Bussell, Cara et al. (2016) The effectiveness and unique contribution of neuropsychological tests and the δ latent phenotype in the differential diagnosis of dementia in the uniform data set. Neuropsychology 30:946-960
Bonham, Luke W; Geier, Ethan G; Fan, Chun C et al. (2016) Age-dependent effects of APOE ε4 in preclinical Alzheimer's disease. Ann Clin Transl Neurol 3:668-77
Ting, Simon Kang Seng; Hao, Ying; Chia, Pei Shi et al. (2016) Clinicopathological correlation of psychosis and brain vascular changes in Alzheimer's disease. Sci Rep 6:20858
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34

Showing the most recent 10 out of 711 publications